Recent research conducted at UT Southwestern Medical Center has unveiled a key protein responsible for necroptosis, a type of programmed cell death characterized by cell membrane rupture, which could pave the way for novel therapeutic approaches in treating various medical conditions. This significant finding was detailed in the journal Nature and is expected to impact our understanding of inflammatory diseases, severe infections, and several forms of cancer.

The Importance of Programmed Cell Death

Programmed cell death plays a crucial role in the body’s lifecycle. It assists in:

  • Tissue development and shaping: Ensuring proper formation of organs and systems during embryonic development.
  • Elimination of damaged cells: Removing cells that are infected, old, or no longer needed to maintain cellular health.
  • Balance between cell proliferation and death: Regulating cellular turnover to prevent diseases such as cancer.

Researcher Ayaz Najafov, Ph.D., emphasized the necessity of understanding these processes, as inflammatory conditions can lead to necroptosis—a cellular event that triggers immune responses to clear away harmful pathogens.

Understanding Necroptosis

Necroptosis differs from other forms of cell death like apoptosis and pyroptosis, primarily due to its inflammatory nature. The necroptotic pathway involves a sequence of molecular events leading to the destruction of the cell membrane. Notably, a protein known as NINJ1 has been implicated in other cell death forms but has yet to be linked to necroptosis. Recognizing the absence of a similar protein in necroptotic processes prompted researchers to investigate other potential mediators.

Discovery of SIGLEC12

The research team, employing CRISPR gene editing technology, discovered that the protein SIGLEC12 plays a pivotal role in necroptotic cell death. Their findings indicate that:

  • When cells lack SIGLEC12, they can still undergo necroptosis; however, their membranes become ballooned without rupturing.
  • Overexpression of SIGLEC12 does not induce membrane rupture, suggesting the need for activation through a cleavage process.
  • A separate protein, TMPRSS4, is responsible for cleaving SIGLEC12, which is a critical step in facilitating the necroptotic process.

These insights highlight how SIGLEC12 serves as a human-specific mediator, presenting a potential target for therapeutic intervention.

Implications for Cancer Treatment

Interestingly, cancer cells are less likely to undergo necroptosis compared to normal cells, providing them a survival advantage. The study noted that mutations in SIGLEC12, common in various tumors, interfere with its cleavage by TMPRSS4 and may impede necroptosis, thus promoting tumor growth. This circumstance may alter patient susceptibility to infections and inflammatory disorders.

In the future, Dr. Najafov anticipates the development of drugs aimed at either targeting SIGLEC12 or TMPRSS4 to manipulate necroptosis in clinical practice, resulting in better management of diseases where necroptosis arises.

Future Research Directions

Continued exploration in this field may open new avenues for therapeutic strategies. Key areas for future investigation include:

  • Evaluating SIGLEC12 and TMPRSS4 inhibitors in clinical settings to assess their efficacy in disease management.
  • Studying the impact of various SIGLEC12 mutations on cell death pathways and sensitivity to therapies.
  • Developing novel drugs that can effectively modulate necroptotic pathways to treat inflammatory and cancerous conditions.

Conclusion

The discovery of SIGLEC12's role in necroptosis offers exciting prospects for therapeutic innovations. By understanding the mechanisms of programmed cell death, researchers can develop targeted therapies aimed at improving outcomes for patients with chronic diseases.

References

Hyunjin Noh et al, SIGLEC12 mediates plasma membrane rupture during necroptotic cell death, Nature (2025). DOI: 10.1038/s41586-025-09741-1

This document is provided for informational purposes only and is not exhaustive of the ongoing research in this rapidly evolving field.